The investigation delves into potential regulatory networks linked to RPL22L1, including its association with tumor microenvironment (TME), tumor mutational burden (TMB)/microsatellite instability (MSI), mRNA stemness index (mRNAsi), and drug sensitivity in LUAD [14]. Here, RPL22L1 is linked to neoplasm.